Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ACP3 | P15309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12815416 | 0.82 | ACHE (0.37) | GAAACP3 | |
| SCHEMBL12815183 | 0.77 | CYP2D6 (0.34) | SLC6A2SLC6A4SLC6A3GAACYP2D6 | |
| SCHEMBL12815424 | 0.76 | — | — | |
| SCHEMBL12814616 | 0.76 | LMNA (0.34) | SLC6A2SLC6A4SLC6A3GAACYP2D6 | |
| SCHEMBL12815009 | 0.76 | CYP1A2 (0.33) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL12815411 | 0.74 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3GAACFTR | |
| SCHEMBL12816039 | 0.72 | TSHR (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6TSHR | |
| SCHEMBL12814587 | 0.71 | OPRL1 (0.36) | GAADPP4 | |
| SCHEMBL12814742 | 0.71 | CALM1 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6TSHR | |
| SCHEMBL7199931 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140012056-A1 | METHOD FOR PRODUCING 1-HEXENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012056-A1 | METHOD FOR PRODUCING 1-HEXENE | AP2A1, AP1M1, ME1 | SLC6A2 4749/4885SLC6A4 4714/4885SLC6A3 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.